Azenta, Inc.
No enriched coverage for $AZTA in the last 7 days.
No SEC Form 4 filings for $AZTA in the last 30 days.
Pomerantz LLP is investigating potential securities fraud claims against Azenta, Inc. (AZTA) on behalf of investors. This comes after Azenta reported lower-than-expected Q2 2026 financial results, including a $149 million goodwill impairment charge and reduced its full-year fiscal 2026 outlook. Following this news, Azenta's stock price dropped by over 25%.
Azenta, Inc. (NASDAQ: AZTA) has granted William E. Martin III, President of Multiomics, 17,790 restricted stock units (RSUs) as compensation under the company's Equity Incentive Plan. These RSUs, valued at $24.24 per share, will vest over three years with installments on April 18, 2027, April 18, 2028, and April 18, 2029. Following this grant, Martin III directly holds 17,790 common shares tied to this award.
Azenta, Inc. (Nasdaq: AZTA) is scheduled to announce its fiscal second quarter 2026 earnings on Wednesday, May 6, 2026, before market open. The company will also host a conference call and live webcast on the same day at 8:30 a.m. Eastern Time to discuss its financial results. Investors and media can access the webcast via Azenta's investor relations website, with a replay available from May 7, 2026.
